TrialBlood cancer journal2021

Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial.

Roberto Mina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.